← 홈

Antibody · 난소암

93개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 93개
AntibodystaleJanssenPhase 2

daratumumab (Darzalex, Mitoxantrone hydrochloride liposome/Dexamethasone/daratumumab)

Relapsed/Refractory Multiple Myeloma · FRα

#FR#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 ACTIVE
AntibodyBiologicstaleMayo ClinicPhase 2

Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine (Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine)

Fallopian Tube Carcinosarcoma; Primary Peritoneal Carcinosarcoma · Fallopian Tube Carcinosarcoma

#FallopianTubeCarcinosarcoma#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleNeoTX Therapeutics Ltd.Phase 1

durvalumab (Imfinzi, Naptumomab estafenatox and durvalumab)

ER+ Breast Cancer; Ovarian Cancer · HER2

#HER2#Antibody#Phase1#항체#면역항체+4
임상시험 1상태 RECRUITING
AntibodystaleAbGenomics B.V Taiwan BranchPhase 2

Neihulizumab Treatment (Neihulizumab Treatment)

Steroid-refractory aGvHD Subsequent to Allogeneic Hematopoietic Cell Transplantation · FRα

#FR#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 DISCONTINUED
AntibodystaleAstraZenecaPhase 2

durvalumab (Imfinzi, Neoadjuvant chemotherapy+Durvalumab+Tremelimumab)

Ovarian Cancer Stage IIIC; Ovarian Cancer Stage IV · Ovarian Cancer Stage IIIC

#OvarianCancerStageIIIC#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 1

durvalumab (Imfinzi, Obinutuzumab, naptumomab estafenatox and durvalumab)

ER+ Breast Cancer; Ovarian Cancer · HER2

#HER2#Antibody#Phase1#항체#면역항체+4
임상시험 1상태 RECRUITING
AntibodystaleNordic Society of Gynaecologica…Phase 2

durvalumab (Imfinzi, Olaparib + durvalumab + UV1)

Ovarian Cancer · Ovarian Cancer

#OvarianCancer#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleNational Cancer Centre, Singapo…Phase 2

Oregovomab (Oregovomab)

Epithelial Ovarian Cancer · Epithelial Ovarian Cancer

#EpithelialOvarianCancer#Antibody#Phase2#항체#면역항체+2
효능 ORR 1%임상시험 1상태 ACTIVE
AntibodystaleRochePhase 2

Orelabrutinib and Rituximab (Orelabrutinib and Rituximab)

Follicular Lymphoma; Relapsed and Refractory Follicular Lymphoma · FRα

#FR#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 RECRUITING
AntibodystaleSCRI Development Innovations, L…Phase 1

PTK787/ZK222584 and Bevacizumab (PTK787/ZK222584 and Bevacizumab)

Refractory Malignancy; Advanced Malignancies · FRα

#FR#Antibody#Phase1#항체#면역항체+4
임상시험 1상태 ACTIVE
AntibodystaleMerckPhase 2

pembrolizumab (Keytruda, Pembrolizumab + Lenvatinib)

Kaposi Sarcoma; Classic Kaposi Sarcoma · FRα

#FR#Antibody#Phase2#항체#면역항체+4
효능 ORR 43.4%임상시험 1상태 DISCONTINUED
AntibodystaleMerckPreclinical

pembrolizumab (Keytruda, Pembrolizumab combined Anlotinib)

High-Grade Serous Ovarian Cancer · High-Grade Serous Ovarian Cancer

#High-GradeSerousOvarianCancer#Antibody#Preclinical#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleGenelux CorporationPhase 2

Platinum-doublet with or without bevacizumab (Platinum-doublet with or without bevacizumab)

Ovarian Cancer; Peritoneal Carcinomatosis · Ovarian Cancer

#OvarianCancer#Antibody#Phase2#항체#면역항체+3
효능 ORR 80%임상시험 1상태 ACTIVE
AntibodystaleJanssenPhase 2

daratumumab (Darzalex, QL2109 or Daratumumab)

Relapsed or Refractory Multiple Myeloma · FRα

#FR#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleRegeneron PharmaceuticalsPhase 2

REGN17372+Linvoseltamab (REGN17372+Linvoseltamab)

Relapsed Refractory Multiple Myeloma (RRMM) · FRα

#FR#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleRochePhase 3

Arm A (Rituximab, Rituximab (Arm A))

Autoimmune Prematur Ovarian Insuffience · Autoimmune Prematur Ovarian Insuffience

#AutoimmunePrematurOvarianInsuffi#Antibody#Phase3#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleRochePhase 3

Arm B (Rituximab, Rituximab (Arm B))

Autoimmune Prematur Ovarian Insuffience · Autoimmune Prematur Ovarian Insuffience

#AutoimmunePrematurOvarianInsuffi#Antibody#Phase3#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleRochePhase 2

Rituximab (Mabthera, Rituximab, Rituximab (Mabthera) , FFP (Fresh Frozen Plasma))

Advanced Refractory Chronic Lymphocytic Leukemia · FRα

#FR#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 ACTIVE
AntibodystaleZibo Municipal HospitalPhase 2

SBRT combined with Tislelizumab followed by Tislelizumab (SBRT combined with Tislelizumab followed by Tislelizumab)

NSCLC; Tislelizumab · FRα

#FR#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 RECRUITING
AntibodystaleJanssenPhase 2

Teclistamab Monotherapy (Teclistamab Monotherapy)

Relapse Multiple Myeloma; Refractory Multiple Myeloma · FRα

#FR#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 RECRUITING

4 / 5 페이지

← 이전다음 →